

Insilico Studies and Screening of Antiepileptic Activity of Leaf Extracts of Plumeria Pudica

¹Manisha B S*, ²Jane B Mathew, ³Jennifer Fernandes

Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences/ Nitte (Deemed to be University), Mangalore- 575018, (Karnataka) India

Date of Submission: 05-06-2024

Date of Acceptance: 15-06-2024

ABSTRACT

Epilepsy is a neurological disorder, affects people of all age groups. There are number of antiepileptic drugs are available, but most of them are highly susceptible to drug interactions and severe adverse effects. As a result, the use of herbal medicine is increasing becoming popular. So, aim of the study is to provide relevant information of antiepileptic potential of phytoconstituents present in Plumeria pudica. Itis a flowering plant belongs to the family Apocynaceae. The pulverized powder of leaves of Plumeria pudicawas extracted with six solvents. Extracts were analysed by insilico study, acute toxicity and invivoantiepileptic activity.GC-MS analysis revealed the presence of 63 phytoconstituents in different extracts.10 phytochemicals were docked towards the MAPK13 complex with inhibitor with the PDB ID 5EKO, which showed that beta-sitosterol(-5.462)had better docking score when compared to the standard diazepam (-4.738). There are no reports of acute toxicity in leaf extracts, hence toxicity study was carried out and found to be safe up to 2000 mg/kg. This is followed by the screening of antiepileptic activity using the pentylenetetrazole model and the electric model.In maximal shock the pentylenetetrazole model, The medium (200mg/kg) and high doses (400mg/kg) of ethanolic extract showed increasing latency to convulsions (114.13±1.36) and (125.52±1.18*) and reduced the duration of convulsions.

KEYWORDS:Plumeria pudica, antiepileptic, acute toxicity, docking, beta-sitosterol

I. INTRODUCTION

Epilepsy is a neurological disorder characterized by recurrent seizures, and it affects millions of people worldwide. It can cause changes in behavior, movements, feelings and levels of consciousness. It includes spasms and violent and uncontrolled spasmodic contraction and relaxations of the voluntary muscles¹. While there

are existing antiepileptic drugs available, they may cause adverse effects and not be effective for all individuals. Therefore, there is a continuous need to explore natural sources, such as plants, for potential antiepileptic compounds. In the present study, the leaves of Plumeria pudicawere taken for extraction of compounds.Plumeria pudica is an ornamental flowering plant that has secondary metabolites with a variety of biological functions. This plant is also known as Nagchampa , wild Plumeria, white frangipani, lei flowers. Plumeria pudica is an evergreen, fast growing shrub containing one or two slender trunks. It can grow up to 5-8 feet height. The leaves are alternate and dark green in colour and they are fiddle shaped or spoon shaped. The plant contain large clusters of bright white flowers upto 3 inches (7.5 cm) with a small yellow center have five petals cover this plant as a beautiful bouquet. So, plant is called as "bridalbouquet"². It belongs to the family Apocynaceae³. It possesses different such as laxative, pharmacological actions carminative, antiallergic, antimicrobial, cytotoxic, antiinflammatory, antileprosy, antiulcer, diuretic properties⁴. anti-ascites and The AChEinhibitoryactivity of leaves of Plumeria pudica onzebrafishbrainwascarriedoutbyPrasad et.al.,(2016). Both in-vitro and in-vivo assessments thatmethanolicextract of Plumeria showed pudicareduces the activity of AChE.Based onthis study, the presentwork was carried out⁵. AChE inhibitors can influence the cholinergic system and modulate neurotransmitter balance in the brain, which may result in antiepileptic effects. Their ability to enhance cholinergic transmission, exert neuroprotective effects, modulate GABAergic neurotransmission, and influence excitatory neurotransmitters contributes to their potential antiepileptic activity.



II. MATERIALS AND METHODS Collection of plant leaves and preparation of extracts

The leaves of Plumeria pudica were collected in the month of June-July from Manjeshwar, Kasaragod district. The extraction of coarsely powdered leaves was done by cold maceration process using chloroform, ethanol, methanol, n-hexane and petroleum ether and water. These extracts were investigated for phytochemical analysis followed by GC-MS analysis, insilicostudy, acute oral toxicity and invivo antiepileptic studies.



Figure 1:Plumeria pudica tree



Figure 2: Leaf

IN-SILICO STUDIES:

Different phytoconstituents present in Plumeria pudicawere screened for their anti-

epileptic properties using in-silico methodologies in Schrödinger software.

A. Data collection:

10 different phytoconstituents from the plant P.pudicawere collected from the GC-MS report. Smiles of these ligands were obtained from the Pub-Chem.

MAPK13 complex with inhibitor with the PDB ID 5EKO was selected as the target protein which was obtained from RCSB PDB with a resolution of 2.00 $Å^{6}$.

B. Ligand preparation: Ligprep:-

A new project was created in a selected working directory, and the SMILES characters were moved into the workspace of Schrodinger Maestro. These ligands are subjected to the Schrodinger suit 2020-4 LigPrep function. The OPLS-3 force field was used to optimize the energy.

C. Protein preparation:

MAPK13 complex with inhibitor with the PDB ID 5EKO was imported from the RCSB PDB and visualized in the Maestro interface. The residues or water molecules beyond 5Å were eliminated.Finally, the protein energy was optimized using the OPLS_2005 force field.

D. Receptor grid generation:

Receptor grid was generated for co-crystal ligands and Diazepam using the GLIDE grid generation wizard. The binding site of the standard drug was chosen and active site grid was generated for molecular docking.

E. Molecular docking:

The energy-minimized ligands are docked with the optimised crystal structure of the protein in this stage. This aids in determining the affinity with which the ligands interact with the protein's active site (Lock - key affinity). Docking is a method for predicting the preferred orientation of one molecule to another when they are linked together to form a stable complex with the lowest overall energy. The level of association or binding affinity between two molecules may be predicted using knowledge about the preferred orientation. The ligands were docked into the protein's glide grid using the standard precision (SP) technique, followed by the extra precision (XP) algorithm in the GLIDE module of the Schrodinger 2020-4 suite device Maestro -11.7.012. The docked posture of ligands and their



interactions were studied once molecular docking was completed.

F. ADME prediction:

ADME calculations of ligands were carried out using the QikProp module of the Schrödinger suite 2020-4, that predicts a molecule's pharmacokinetic properties relating to its physicochemical properties. The parameters like H bond donor and acceptors, molecular volume, log P value, PSA are expected to be within acceptable range when compared to standard values.

G. MM/GBSA simulations:

Schrodinger Prime software and molecular mechanics/generalized Boltzmann Surface area methodology (MM/GBSA) were used to calculate the binding Free energy for the protein and group of ligands.

ACUTE ORAL TOXICITY STUDY

Acute toxicity studies were carried out using healthy female swiss albino mice weighing 25-30g of age 8-12 weeks older. Animals were obtained from central animal house, Nitte Centre for Animal Research and Experimentation (NUCARE), Paneer, Mangalore after getting approval from the IAEC (Reg.No: 1781/PQ/ERe Bi/S/2014/CPCSEA). The animals were housed in different cages in the animal room with a maintained temperature of 22°C (±3°C).Animal room was provided with artificial lighting with 12 hours of light and 12 hours dark cycle. Animals were provided with the standard dry pellet, purified water with ad libitum.

The acute oral toxicity study of plant extract was carried out by using Swiss albino mice by up and down method as per OECD 425 guidelines⁷. Animals were fasted prior to the dosing (food but not water withheld for 3-4 hours). The fasted body weight of each animal was determined and the dose was calculated according to the body weight. After the substance has been administered, food was withheld for 3-4 hours. Where a dose is administered in fractions over a period of time, it may be necessary to provide the animals with food and water depending on the length of the period. Animals were observed individually at least once during the first 30 minutes after dosing, periodically during the first 24 hours and daily thereafter for a total 14 days⁸. If the animal survives, the second animal receives a higher dose. If the first animal dies, the second animal receives a lower dose. In this present study, initially a dose of 1000mg/kg of ethanolic extract was administered to the mice. There was no behavioural changes or symptoms of toxicity were seen in this dose level. So, the dose was increased to 1500mg/kg and up to 2000mg/kg. Animals were observed for the following parameters :

a) Behavioural profile

Awareness : alertness, visual placing, stereotypy, passivity Mood : grooming, restlessness, irritability, fearfulness

b) Neurological profile

Motor activity, spontaneous activity, reactivity, touch response, pain response, startle response, tremor, gait, grip strength. Pinna, corneal reflex.

c) Autonomic profile :

Writhing, defecation, urination, piloerection, heart rate, respiratory rate

IN-VIVO ANTIEPIPLEPTIC SCREENING Selection of doses

The doses for the antiepileptic study were selected based on the acute toxicity study. From the study it was found that ethanolic extract of plant leaves was found safe at the concentration of 2000mg/kg and not toxic effects were seen in Swiss albino mice.Therefore, $1/5^{\text{th}}$ (400mg/kg), $1/10^{\text{th}}(200\text{mg/kg}), 1/20^{\text{th}}(100\text{mg/kg})$ of the LD50 dose were selected for the study.

Pentylenetetrazole induced convulsion in mice^{9,10,11}:

Experimental design: The animals were divided into 5 groups (n=6). The control group was administered with 0.6% w/v of CMC orally. The standard group receives diazepam at the dose of 5mg/kg administered intraperitoneally. The test extract was screened at three dose levels viz. low (200mg/kg), and (100 mg/kg),medium high (400mg/kg). The extract was administered orally. After 1 hour, PTZ was injected intraperitoneally at the dosage of 80mg/kg and observed up to 30 minutes. The latency to onset of seizure, tonic convulsions, and status of each animal was observed.

Maximal electroshock induced convulsions in mice^{9,10,11,12}:

Experimental design: Animals were divided into 5 groups (n=6). Animals were checked for sensitivity to electric shock 24hr before administration of test



compounds and those animals which fail to show hind limb tonic extension were rejected. The control group received 0.6% w/v of CMC orally and the standard group received phenytoin (25mg/kg) intraperitoneally. The test extract was screened at three dose levels viz. low (100mg/kg), medium (200mg/kg) and high (400mg/kg). The extract was administered orally. After 60 minutes of administration of test extract, 60Hz alternating current of 150mA intensity for 0.2 sec was given using corneal electrodes. The animals were observed for the various phases of convulsions like tonic, flexion, extension, stupor and mortality due to convulsions. The onset of time of seizures, duration of tonic hind limb extension and mortality for each animal wasobserved. Decrease in duration of hind limb extension was considered as protective action. Abolition of the extensor phase was considered as anti-epileptic effect.

Statistical analysis

Graphpad Prism 8.0.2 software was used to calculate all of the data statistically. One-way analysis of variance(ANOVA) was performed on data from six animals per group. The experimental values were expressed as the mean \pm Standard Error of Mean (SEM). Significance was determined by p values below 0.05,denoted by asterisks (*p < 0.05, **p<0.01, and ***p< 0.001).

IN-SILICO STUDIES:

III. RESULTS AND DISCUSSION

Ligand	Docking	MMGBSA	HPI	PI	HB	PC
	score	dG Bind				
Diazepam	-4.738	-45.58	ALA52		MET110	LYS116
(standard)			ILE85			
			LEU167			
			MET107			
			PRO108			
			PHE109			
			MET110			
			VAL31			
			ALA157			
			VAL39			
N-hexadecanoic	-3.343	-90.49	LEU75	THR112	ASP113	
acid			LEU76	GLN111		
			VAL39			
			VAL31			
			ALA157			
			MET110			
			PHE109			
			MET107			
			ALA52			
			LEU167			
			ILE85			
			PHE169			
			LEU171			
Phytol	-4.802	-92.81	LEU75	THR112	ASP113	
5			LEU76	GLN111		
			LEU171			
			PHE169			
			LEU167			
			ILE85			
			VAL31			
			ALA157			
			MET110			
			PRO108			



	1		MET107	Γ	T	1
			MET107			
			ALA52			
			VAL39			
Beta-sitosterol	-5.462	-63.13	LEU171	THR112	MET110	
			PHE169	GLN111		
			LEU167			
			LEU75			
			LEU76			
			ILE85			
			ALA52			
			ALA157			
			LEU105			
			MET107			
			PRO108			
			PHE109			
			MET110			
			VAL31			
			VAL31 VAL39			
Oleic acid	-3.283	-102.55	LEU167	THR112	ASP113	┠─────┦
OTER actu	-3.203	-102.33	PHE169		LYS116	
			LEU171		LISIIO	
			LEU75			
			LEU76			
			MET107			
			PRO108			
			PHE109			
			MET110			
			ILE85			
			ALA52			
			VAL31			
			VAL39			
			ALA157			
Squalene	-4.801	-104.81	MET107	THR112		
_			PRO108	GLN111		
			PHE109	SER33		
			MET110	SER38		
			ALA157			
			LEU75			
			LEU76			
			LEU171			
			PHE169			
			LEU167			
			VAL31			
			ALA52			
			ILE85			
			ALA35			
			VAL39			
Octadecanoic	0.042	-93.01				<u> </u>
	-0.943	-93.01	LEU171			
acid,ethyl ester			PHE169			
			LEU167			
			LEU76			
			LEU75			
			ALA52			



VAL31 METT10 PR0108 PR019 ILESS TYR36VAL31 MET107 VAL39MET107 PR019 ILESS TYR36MET110 PHE169 LEU167 LEU76 LEU75 ALA52 ILESS MET107 VAL39MET110 PHE109 PHE109 MET110 VAL31 VAL39Frgost-5,8(14)- dien-3-ol-4.308-62.35LEU167 LEU76 ILESS MET107 VAL31 VAL39 VAL39GLN111 HB101 HB102 HB109 MET110 VAL31 VAL39ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU76 LEU76 LEU76 ILEU76 HE109 MET110 ALA52 ALA157 VAL39STR12 CIN11 LEU76 HE109 MET110 ALA52 ALA157 VAL31 VAL39STR12 CIN111 LEX5 MET107 HID309,12 octadecadienoic acid(z.2)-methyl ester-2.598-88.19HL85 VAL31 LEU76 LEU75THR112 LV161 LEU56 MET110 ALA52 LEU57 HE109 MET110 ALA52 LEU76 LEU167 HE109 MET110 ALA52 HE109 MET110 ALA52 HE109 MET110 ALA52 LEU76 LEU76 LEU76 LEU77 HE109 MET100 ALA52 HE109 MET100 ALA52 HE109 MET100 ALA52 HE109 MET100 ALA52 HE109 MET100 ALA52 HE109 MET100 ALA52 HE109 MET100 ALA52 HE109 MET100 ALA52 HE109 MET100 ALA52 HE109 MET100 ALA52 HE109 MET100 HE109 MET100 ALA52 HE109 MET100 ALA52 HE109 MET100 HE109 MET100 HE109 MET100 HE109 MET100 HE109 		1		L =			·
PHE109 PR0108 MET107 VAL39 LESS TYR36PHE109 PR0108 MET107 VAL39MET110Hexadecenoic acid,ethyl ester-4.521-110.49LEU171 LEU76 LEU76 LEU76 LESS MET107 PR0108 PHE109 MET110 VAL31 VAL31 VAL31 VAL31 VAL31 VAL31 VAL39MET110 MET110 ALA52 LESS MET107 PR0108 PHE109 MET110 ALA52 MET107 PR0108 PHE109 MET110 ALA52 MET107 PR0108 PHE109 MET110 ALA52 ALA517 VAL31 VAL39ASP168 ASP169 ASP169							
PR0108 MET107 VAL39 LE85 TYR36MET110Hexadecenoic acid,ethyl ester-4.521-110.49LEU171 PHE169 LEU167 LEU75 ALA52 HL285 MET107 PR0108 PHE109 MET110 VAL39 TYR36MET110Ergost-5.8(14)- dien-3-ol-4.308-62.35LEU167 LEU76 ALA52 HE109 MET110 VAL39 TYR36GLN111 HID30ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU76 LEU76 LEU76 ALA52 HE109 MET110 ALA52 ALA157 VAL39JASP1689,12 octadecadienoic acid(z.2)-methyl ester-2.598-88.19ILE85 PHE109 MET106 ALA52 ILE85 ALA157 VAL31 VAL31 VAL39JTR112LYS1169,12 octadecadienoic ester-2.598-88.19ILE85 PHE109 MET110 ALA52 ILE85 ALA157 VAL31 VAL31 VAL39JTR112LYS116							
MET107 VAL39 ILE85 TYR36MET107 VAL39 ILE85 TYR36MET10Hexadecenoic acid,ethyl ester-4.521-110.49IEU171 IEU76 IEU76 IEU76 ALA52 ILE85 MET107 PR0108 PHE109 MET110 VAL31 VAL31 VAL31 VAL31 VAL39MET110Ergost-5.8(14)- dien-3-ol-4.308-62.35IEU167 IEU167 NAL312 VAL31 VAL31 VAL39GLN111 HID30Pentanoic acid,10- undecenyl ester-4.308-62.35IEU167 IEU167 NAL312GLN111 HID30Pentanoic acid,10- undecenyl ester-2.655-85.23IEU76 IEU76 NAL312ASP1689,12 octadcadienoic acid(x,2)-methyl ester-2.598-88.19TIR85 IIE85 NA157 NAL31 VAL31 VAL30THR112 ILV769,12 octadcadienoic acid(x,2)-methyl ester-2.598-88.19IIE85 IEE0167 IEE0167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 PHE169 IEU167 IEU167 IEU506THR112 IVS116				PHE109			
VAL39 ILE85 TYR36MET110Hexadecenoic acid,ethyl ester-4.521-110.49PLEU171 PLEU171 LEU76 LEU75 ALA52 ILE85 MET107 PR0108 PHE109 MET110 VAL39 TYR36MET110Ergost-5.8(14)- dien-3-ol-4.308-62.35LEU76 LEU76 MET107 NAL39 TYR36GLN111 THR112 HD30 ALA52 ALA52 ALA53ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU76 LEU76 MET107 NAL39 VAL39ASP1689,12 octadecadienoic acid(z.2)-methyl ester-2.598-88.19ILE85 PHE109 MET107 NAL31 VAL31 VAL31 VAL39THR112 HD309,12 octadecadienoic acid(z.2)-methyl ester-2.598-88.19ILE85 PHE109 MET107 PHE169 LEU167 MET106 LEU167 MET108 PHE109 MET1008 PHE109 MET1007 PHE109 LEU167 MET100 PHE109 MET100 PHE109 MET107 PHE109 LEU76THR112 LYS116LYS116				PRO108			
IntersectionIntersectionIntersectionIntersectionIntersectionIntersectionHexadecenoic acid,ethyl ester-4.521-110.49LEU171 PHE169 LEU167 LEU76 LEU76 LEU76 LEU76 LEU76 LEU76 HE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE107 ILE85 PHE107 PHE107 ILE85 PHE107 PHE109 PHE109 PHE109 PHE107 ILE85 PHE107 PHE109 PHE10				MET107			
IntersectionIntersectionIntersectionIntersectionIntersectionIntersectionHexadecenoic acid,ethyl ester-4.521-110.49LEU171 PHE169 LEU167 LEU76 LEU76 LEU76 LEU76 LEU76 LEU76 HE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE109 PHE107 ILE85 PHE107 PHE107 ILE85 PHE107 PHE109 PHE109 PHE109 PHE107 ILE85 PHE107 PHE109 PHE10							
Image: marked box series of the state of							
$ \begin{array}{c} \text{Hexadecenoic} \\ \text{acid,ethyl ester} \\ acid,ethyl ester$							
acid,ethyl ester acid,ethyl ester acid,ethyl ester 12076 LEU76 LEU75 ALA52 LEU76 LEU75 ALA52 NAL39 TYR36 Ergost-5,8(14)- dien-3-ol 4.308 -4.308 -4.308 -62.35 LEU76 LEU76 LEU76 NAL31 VAL39 TYR36 Ergost-5,8(14)- dien-3-ol -2.655 -2.656	Hevadecenoic	-4 521	-110/19			MET110	
LEU167 LEU75 ALA52 ILE85 MET107 PR0108 PHE109 MET110 VAL31 VAL39 ASP168 Ergost-5,8(14)- dien-3-ol -4.308 -62.35 LEU167 LEU76 THR112 HID30 ASP168 Pentanoic acid.10- undecenyl ester -2.655 -85.23 LEU75 LEU76 LEU76 LEU76 LEU76 -4.308 Pentanoic acid.10- undecenyl ester -2.655 -85.23 LEU76 LEU76 LEU76 LEU76 LEU171 PHE169 LEU171 PHE169 LEU171 PHE169 LEU167 MET110 ALA52 ILE85 ALA157 VAL31 VAL39 -2.558 -85.23 LEU75 LEU76 LEU76 LEU171 PHE169 LEU171 PHE169 LEU167 MET110 ALA52 ILE85 ALA157 VAL31 VAL39 -2.598 -88.19 ILE85 VAL31 VAL39 THR112 LYS116		-4.521	-110.47			WILLING	
LEU76 LEU75 ALA52 ILE85 MET107 PR0108 PHE109 MET110 VAL39ASP168Ergost-5.8(14)- dien-3-ol-4.308-62.35LEU167 LEU167 MET100 MET110 ALA52 ALA157 VAL31 VAL31 VAL39ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU171 NET107 PR0108 ALA52 LEU167 LEU167 LEU167 MET109 ALA52 LEU167 LEU167 MET109 MET109 VAL31 VAL31 VAL39ASP1689,12 octadecadienoic acid(z,2)-methyl ester-2.598-88.19ILE85 PHE109 ALA157 VAL31 LEU76 LEU76 LEU76 LEU76 LEU77 HE109 ALA157 VAL31 VAL31 LEU76THR112 LYS116	acia, curyr ester						
LEU75 ALA52 ALA53 LE85 MET107 PR0108 PR110 VAL31 VAL31 VAL33 TYR36LEU167 GLN111 THR112 HID30ASP168 ASP168Ergost-5,8(14)- dien-3-ol-4.308 -62.35-62.35LEU167 LEU167 HID30 MET107 ALA52 ALA517 VAL31 VAL39GLN111 THR112 HID30ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU76 LEU77 LEU76 LEU171 PHE109 MET110 ALA52 ALA51 VAL31 VAL39LEU76 LEU171 LEU167 MET107 PHE109 MET110 ALA52 LEU176 LEU171 PHE109 MET110 ALA52 LEU75 LEU176 LEU171 PHE109 MET110 ALA52 LEU76 LEU171 PHE109 MET110 ALA52 LEU76 LEU171 PHE109 MET110 ALA52 LEU76 LEU171 LE85 ALA157 VAL31 VAL31 VAL31 VAL31 LEU167 PHE109 LEU171 LEV161LYS116							
ALA52 ILE83 MET107 PR0108 PHE109 MET110 VAL31 VAL39 TYR36ALA52 ILE83 PHE109 MET1107 HID30ASP168Ergost-5,8(14)- dien-3-ol-4.308-62.35LEU167 ILE0167 MET107 ALA52 ALA157 VAL31 VAL39GLN111 HID30ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU75 LEU76 LEU76 LEU167 MET100 ALA52 ALA157 VAL31SP1689,12 octadecadienoic acid(z,2)-methyl ester-2.598-88.19ILE85 VAL31 VAL31 VAL31THR112 LV16							
Image: series of the series							
MET107 PRO108 PHE109 MET110 VAL31 VAL32 MET107 PRO108 PHE109 MET110 VAL31 VAL39 Image: Constraint of the second s							
PR0108 PHE109 MET110 VAL31 VAL39 TYR36 PRO108 PHE109 VAL31 VAL39 TYR36 PRO108 PHE109 MET110 ASP168 Ergost-5,8(14)- dien-3-ol -4.308 -62.35 LEU167 LEU76 PHE109 MET110 ALA52 ALA157 VAL31 VAL39 GLN111 THR112 HID30 ASP168 Pentanoic acid,10- undecenyl ester -2.655 -85.23 LEU75 LEU76 LEU176 LEU171 PHE169 LEU107 MET110 ALA52 ILE85 ALA157 VAL31 VAL39 -2.655 -85.23 LEU76 LEU176 LEU171 PHE169 LEU167 PKE109 MET110 ALA52 ILE85 ALA157 VAL31 VAL39 LYS116 9,12 octadecadienoic acid(z,z)-methyl ester -2.598 -88.19 ILE85 VAL31 LEU167 PHE169 LEU171 LEU176 THR112 LYS116							
PHE109 MET110 VAL39 TYR36 PHE109 MET110 VAL39 TYR36 Image: Constraint of the system of the system ASP168 Ergost-5,8(14)- dien-3-ol -4.308 -62.35 LEU167 LEU76 THR112 MET107 HID30 GLN111 HID30 ASP168 Pentanoic acid,10- undecenyl ester -2.655 -85.23 LEU75 LEU76 LEU76 LEU171 PHE169 LEU171 PHE169 LEU167 MET100 ALA52 ILE85 ALA157 VAL31 VAL39 -2.598 -88.19 LE85 VAL31 VAL31 VAL39 -1121 LEU5 9,12 octadecadienoic acid(z,z)-methyl ester -2.598 -88.19 ILE85 VAL31 LEU167 PHE169 LEU171 LEU167 PHE169 LEU176 THR112 LYS116							
MET110 VAL31 VAL31 VAL39MET110 VAL31 VAL39MET110 VAL31 VAL39ASP168Ergost-5,8(14)- dien-3-ol-4.308-62.35LEU167 MET107 MET107 MET109 MET110 ALA52 ALA157 VAL31 VAL31 VAL31 VAL39ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU76 LEU171 PHE169 MET110 ALA52 LEU76 LEU167 MET107 PR0108 PHE109 MET110 ALA52 LEU167 MET107 PR0108 PHE109 MET110 ALA52 LEU167 MET100 PR0108 PHE109 MET110 ALA52 LEU57 LEU167 MET107 PR0108 PHE109 MET110 ALA52 LEU57 LEU167 MET107 PR0108 PHE109 MET110 ALA52 LEU57 LEU167 MET100 PR0108 PHE109 MET110 ALA52 LEU57 LEU167 MET100 PR0108 PHE109 MET110 ALA52 LEU57 LEU167 PHE109 MET110 ALA52 LEU57 LEU167 HE109 LEU167 PHE109 LEU171 LEU176LYS116							
VAL31 VAL39 TYR36VAL39 VAL39 TYR36Ergost-5,8(14)- dien-3-ol-4.308-62.35LEU167 LEU167 MET107 ALA52 ALA157 VAL31 VAL39GLN111 THR112 HID30ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU76 LEU76 LEU76 LEU171 PHE169 LEU167 MET110 ALA52 LEU75 LEU76 LEU76-85.23LEU75 LEU76 LEU769,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19ILE85 VAL31 LEU167 MET107 PHE169 LEU171 LEU167 MET110 ALA52 LE09 MET110 ALA52 LEU57 LEU167 MET107 PRO108 PHE109 MET110 ALA52 LEU57 LEU167 MET107 PRO108 PHE109 MET110 ALA52 LEU57 LEU167 PHE109 MET110 ALA52 LEU167 PHE109 MET110 ALA52 LEU167 PHE109 MET110 ALA52 LEU167 HE109 MET110 ALA52 LEU167 PHE109 LEU171 LEU167 PHE169 LEU171 LEU167 PHE169 LEU171 LEU167 PHE169 LEU171 LEU167 PHE169 LEU171 LEU167LYS116							
Ergost-5,8(14)- dien-3-ol-4.308-62.35LEU167 LEU76 MET107 HE109 MET110 ALA52 ALA157 VAL31GLN111 HID30 HID30 HID30 HE130 ALA52 ALA157 VAL31ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU76 LEU76 LEU171 PHE169 LEU167 MET110 ALA52 ILE85 HID30-2.6559,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19HE85 VAL31 VAL31 VAL31 VAL31 LEU167 MET110 ALA52 LEU76 LEU167 MET107 PR0108 PHE169 LEU167 MET110 ALA52 ILE85 VAL31 VAL31 VAL31 VAL31THR112 LYS116				MET110			
Ergost-5,8(14)- dien-3-ol-4.308-62.35LEU167 LEU76 MET107 HE109 MET110 ALA52 ALA157 VAL31GLN111 HID30 HID30 HID30 HE130 ALA52 ALA157 VAL31ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU76 LEU76 LEU171 PHE169 LEU167 MET110 ALA52 ILE85 HID30-2.6559,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19HE85 VAL31 VAL31 VAL31 VAL31 LEU167 MET110 ALA52 LEU76 LEU167 MET107 PR0108 PHE169 LEU167 MET110 ALA52 ILE85 VAL31 VAL31 VAL31 VAL31THR112 LYS116				VAL31			
Ergost-5,8(14)- dien-3-ol-4.308-62.35LEU167 LEU76 NET107 HE109 MET110 ALA52 VAL31 VAL39GLN111 THR112 HID30ASP168Pentanoic acid,10- undecenyl ester-2.655-85.23LEU76 LEU76 LEU171 PHE169 LEU167 MET110 ALA52 LEU167 LEU167 NET110 ALA52 LEU167 LEU167 NET110 ALA52 LEU167 LEU167 NET110 ALA52 LEU167 LEU167 NET110 ALA52 HE109 MET110 ALA52 LEU167 NET110 ALA52 HE109 NET110 ALA52 LEU167 HE109 NET110 ALA52 HE109 NET110 ALA52 LEU167 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 NET110 ALA52 HE109 HE109 NET110 ALA52 HE109 				VAL39			
$ \begin{array}{c} \mbox{Ergost-5,8(14)-} \\ \mbox{dien-3-ol} \\$							
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Ergost-5.8(14)-	-4,308	-62.35		GLN111	ASP168	
Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU76 LEU171 PHE169 LEU167 MET1100 ALA52 LEU76 LEU76 LEU171 PHE169 LEU167 MET1100 ALA52 LEU85 ALA157 VAL31 VAL39HID30 HEID30 <td>dien-3-ol</td> <td>1.500</td> <td>02.35</td> <td></td> <td></td> <td>1101 100</td> <td></td>	dien-3-ol	1.500	02.35			1101 100	
Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU76 LEU171 							
PHE109 MET110 ALA52 ALA157 VAL31 undecenyl esterPHE109 MET110 ALA52 ALA157 VAL39PHE109 MET107 LEU76 LEU171 PHE169 LEU167 PRO108 PHE109 MET110 ALA52 ILE85 ALA157 VAL31 VAL31 VAL31 VAL31 VAL31 VAL31 VAL31 VAL31 LEU167 PHE169 LEU167 PHE169 LEU171 LEU171 LEU167 PHE169 LEU171 LEU171 LEU171 LEU171LYS116					IIID30		
9,12 octadecadienoic acid(z,z)-methyl-2.598-88.19ILE85 VAL31 VAL30THR112LYS1169,12 octadecadienoic acid(z,z)-methyl-2.598-88.19ILE85 VAL31 VAL30THR112LYS116							
Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU76 LEU171 PHE169 LEU167 MET107 PRO108 PHE109 MET110 ALA52 ILE85 ALA157 VAL31 VAL31 VAL39LSU9,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19ILE85 VAL31 LEU167 MET169 LEU167 MET100 ALA52 ILE85 ALA157 VAL31 LEU167THR112LYS116							
ALA157 VAL31 VAL39ALA157 VAL31 VAL39Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU76 LEU171 PHE169 LEU167 MET107 PRO108 PHE109 MET110 ALA52 ILE85 ALA157 VAL31 VAL39Image: Comparison of the second sec							
Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU76 LEU171 PHE169 LEU167 MET107 PRO108 PHE109 MET110 ALA52 ILE85 ALA157 VAL31 VAL31 VAL39LS19,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19ILE85 VAL31 LEU167 PHE169 LEU167 PHE169 LEU171 LEU76THR112LYS116							
Pentanoic acid,10- undecenyl ester-2.655-85.23LEU75 LEU76 LEU171 PHE169 LEU167 MET107 PRO108 PHE109 MET110 ALA52 ILE85 ALA157 VAL31 VAL39LEV LSLEUS10 LEU167 MET110 ALA52 ILE85 ALA157 VAL31 LEU167 PHE169 LEU167 PHE169 LEU171 LEU167 PHE169 LEU171 LEU167 PHE169 LEU171 LEU167 PHE169 LEU171 LEU167 PHE169 LEU171 LEU167 PHE169 LEU171 LEU167THR112 LYS116LYS116							
$\begin{array}{c c c c c c c c c c c c c c c c c c c $							
undecenyl ester undecenyl ester 9,12 octadecadienoic acid(z,z)-methyl ester Unit diamond with the start of the start				VAL39			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Pentanoic acid,10-	-2.655	-85.23	LEU75			
9,12 octadecadienoic acid(z,z)-methyl-2.598-88.19ILE85 ALA157 VAL31 LEU167 PRO108 PHE109 MET110 ALA52 ILE85 ALA157 VAL31 LEU167 PHE169 LEU171 LEU76THR112LYS116	undecenyl ester			LEU76			
9,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19ILE85 NALA157 VAL31 LEU167 PHE169 ILEU171 LEU176THR112LYS116	•			LEU171			
9,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19ILE85 NALA157 VAL31 LEU167 PHE169 ILEU171 LEU176THR112LYS116				PHE169			
9,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19ILE85 VAL31 VAL31 LEU167 PHE169 LEU171 LEU76THR112LYS116							
9,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19ILE85 VAL31 VAL31 LEU167 PHE169 LEU171 LEU76THR112LYS116							
9,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19ILE85 VAL31 VAL31 LEU167 PHE169 LEU171 LEU76THR112LYS116							
9,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19ILE85 VAL31 VAL31 LEU167 HHE169 LEU171 LEU76THR112LYS116							
9,12 octadecadienoic acid(z,z)-methyl ester-2.598-88.19ILE85 NALA157 VAL31 LEU167 PHE169 LEU171 LEU76THR112LYS116							
9,12 octadecadienoic acid(z,z)-methyl ester - 2.598 -88.19 ILE85 Deter - 2.598 -88.19 ILE85 Deter - 2.598 -88.19 ILE85 Deter - 2.598 -88.19 Determined and the second seco							
9,12 octadecadienoic acid(z,z)-methyl ester - 2.598 -88.19 ILE85 pHE169 LEU171 LEU167 PHE169 LEU171 LEU76							
9,12 octadecadienoic acid(z,z)-methyl ester							
9,12 octadecadienoic acid(z,z)-methyl ester							
9,12 octadecadienoic acid(z,z)-methyl ester							
octadecadienoicVAL31acid(z,z)-methylLEU167esterPHE169LEU171LEU76				VAL39			
octadecadienoicVAL31acid(z,z)-methylLEU167esterPHE169LEU171LEU76							
octadecadienoicVAL31acid(z,z)-methylLEU167esterPHE169LEU171LEU76	9,12	-2.598	-88.19	ILE85	THR112	LYS116	
acid(z,z)-methyl LEU167 PHE169 LEU171 LEU76							
ester PHE169 LEU171 LEU76							
LEU171 LEU76	-						
LEU76	05001						
LEU/3							
				LEUIJ		I	<u> </u>



LEU105	
ALA52	
MET107	
PRO108	
PHE109	
MET110	
VAL39	
VAL158	
ALA157	

*HPI- Hydrophobic interaction, PI - Polar interaction with ligand, HB - Hydrogen bonding, PPS - Pi-pi stacking, PC - Pi cations

Ligand	Molecular weight	Molecular volume	PSA	QPlogPw	H- acceptor	H-donor
Acceptable range	130.0 -725.0	500.0 – 2000.0 –	7.0 - 200.0	4.0 - 45.0	2.0 – 20.0 –	0.0 - 6.0
Diazepam (standard)	284.744	896.098	46.901	7.188	4	0
9,12 octadecadienoic acid(z,z)-methyl ester(P10)	294.476	1281.425	35.783	1.044	2	0
Pentanoic acid,10- undecenyl ester (P9)	254.412	1135.442	36.224	1.122	2	0
Ergost-5,8(14)- dien-3-ol (P8)	398.671	1409.695	21.042	3.789	1.7	1
Hexadecenoic acid,ethyl ester (P7)	284.481	1270.961	35.034	0.557	2	0
Octadecanoic acid,ethyl ester (P6)	312.535	1389.721	36.645	0.296	2	0
Squalene(P5)	410.725	1758.771	0.000	-3.083	0	0
Oleic acid(P4)	282.465	1224.029	51.734	2.463	2	1
Beta-sitosterol(P3)	414.713	1457.614	22.279	3.670	1.7	1
Phytol (P2)	296.535	1294.708	23.019	2.040	1.7	1
N-hexadecanoic acid (P1)	256.428	1116.919	50.333	2.363	2	1

	Table 3: Lipinski's Rule of five							
Ligand	Molecular weight	HB Donor	HB Acceptor	QPlog p o/w	RO5			
Acceptable range	≤500	≤ 5	≤ 10	< 5	≤ 5			
Diazepam (standard)	284.744	0	4	2.992	0			
9,12 octadecadienoic acid(z,z)- methyl	294.476	0	2	6.346	1			



254.412	0	2	5.436	1
398.671	1	1.7	7.214	1
284.481	0	2	6.248	1
312.535	0	2	7.003	1
410.725	0	0	13.918	1
282.465	1	2	5.905	1
414.713	1	1.7	7.473	1
296.535	1	1.7	6.334	1
256.428	1	2	5.247	1
	398.671 284.481 312.535 410.725 282.465 414.713 296.535	398.671 1 284.481 0 312.535 0 410.725 0 282.465 1 414.713 1 296.535 1	398.671 1 1.7 284.481 0 2 312.535 0 2 410.725 0 0 282.465 1 2 414.713 1 1.7 296.535 1 1.7	398.671 1 1.7 7.214 284.481 0 2 6.248 312.535 0 2 7.003 410.725 0 0 13.918 282.465 1 2 5.905 414.713 1 1.7 7.473 296.535 1 1.7 6.334

Table 4:ADMET properties of the compounds


Ligand	QPPCaco	% Human	CNS	BBB	hERG
-	_	Oral			
		Absorption			
Acceptable	<25 poor, >500	1-low	-2 (inactive),	-3.0 - 1.2	concern below
range	great	2-medium	+2 (active)		-5
		3-high			
Diazepam	2684.726	3	1	0.199	-5.097
(standard)					
9,12	2998.954	1	-1	-0.920	-5.670
octadecadienoic					
acid(z,z)-					
methyl					
ester(P10)					
Pentanoic	3322.530	3	-1	-0.786	-5.509
acid,10-					
undecenyl ester					
(P9)					
Ergost-5,8(14)-	4026.510	1	0	-0.205	-4.547
dien-3-ol (P8)					
Hexadecenoic	3131.098	1	-1	-0.964	-5.559
acid,ethyl ester					
(P7)					
Octadecanoic	2941.715	1	-2	-1.152	-5.863
acid,ethyl ester					
(P6)					
Squalene(P5)	9906.038	1	2	2.038	-6.224
Oleic acid(P4)	227.332	1	-2	-1.599	-3.644
Beta-	3404.598	1	0	-0.340	-4.545
sitosterol(P3)					
Phytol (P2)	2844.938	1	-1	-0.923	-5.318




N-	267.129	3	-2	-1.396	-3.236	
hexadecanoic						
acid (P1)						

The docking results showed that betasitosterol and phytol had better dockingscores when compared to the standard diazepam. Beta-sitosterol was exhibited the best docking score which was -5.462 when compared to diazepam which was -4.738. The docking score of other compounds i.e., N-hexadecanoic acid, oleic acid, squalene, octadecanoic acid, ethyl ester, hexadecenoic acid,ethyl ester,ergost-5,8(14)-dien-3-ol,pentanoic acid,10- undecenyl ester,9,12 octadecadienoic acid(z,z)-methyl ester was found to be -3.343,-3.283,-4.801,-0.943,-4.521,-4.308,-2.655,-2.598 respectively. All compounds except squalene possess required physicochemical properties. These compounds possessed molecular weight, hydrogen bond donor, hydrogen bond acceptors in the normal

range. The one violation is due to increased QPlog p o/w than the recommended range which implies reduced permeability through biological membranes. Yet, due to only one violation from the rule of 5 the compounds are said to have oral bioavailability. As per the in-silico report, almost all the compounds were having similar to better affinity while interacting with the protein whereas phytol and beta-sitosterol were found to have the best affinity with lowest binding energy. In case of physicochemical, ADME properties and Lipinski Rule of five, Pentanoic acid, 10-undecenyl esterwas found to be the best candidate with significant docking result similar to that of standard Diazepam along with good physicochemical and ADME properties









ACUTE TOXICITY STUDY

The acute oral toxicity study was carried out on Swiss albino mice by using up and down method according to the OECD guidelines 425.The ethanoilc extract of the leaves of Plumeria pudica at the dose of 2000mg/kg, did not show any behavioral changes or symptoms of toxicity during the short-term (48 h) and long-term (14 days) observation period. Hence, the plant extract was found to be safe up to the tested dose of 2000mg/kg, p.o.

EVALUATION OF INVIVO ANTIEPILEPTIC ACTIVITY Pentylenetetrazole induced convulsions:

Table 5 : Effect of ethanolic extract of P.pudica leaves in the PTZ model

			Tonic convulsi on (Sec/ 0.5hr)	Status of after 0.5hrs	the animal	Status of animal after 24hrs	
				No of animals alive	% protection	No of animal alive	% Protecti on
Group s	Treatment	Latency (Sec/ 0.5hr)					
Ι	Control	58.26 ± 0.87	99.52± 0.56	0/6	0	0/6	0
П	Diazepam (5mg/kg)	165.96± 0.57*	123.56± 0.24**	6/6	100	6/6	100
III	Low (100mg/kg)	$65.05 \pm 0.41 **$	112.58± 1.05*	5/6	83.33	5/6	83.33
IV	Medium (200mg/kg)	114.13± 1.36*	135.36± 0.76ns	6/6	100	6/6	100
IV	High (400mg/kg)	125.52± 1.18*	98.38± 0.57*	6/6	100	6/6	100

Values are expressed as mean \pm SEM for 6 animals; ***p < 0.0001, *p < 0.001 and *p < 0.05 Vs control.




Figure 4: Effect of P.pudica leaf extract on latency and tonic convulsions in PTZ model

In PTZ model, ethanolic leaf extracts at the dose of 100mg/kg, 200mg/kg and 400mg/kg were administered to the mice and latency to onset of seizures and tonic convulsions were measured. The results indicated a significant decrease in duration of convulsions across the three doses of ethanolic extract as compare to control and standard values. The standard diazepam showed




longer latency to tonic convulsions $(165.96\pm0.57*\text{seconds})$ and shorter duration of convulsions $(123.56\pm0.24**)$ compare to control group.The medium and high dose of ethanolic extract showed similar efficacy in increasing latency to convulsions $(114.13\pm1.36*)$ and


 $(125.52\pm1.18^*)$ and reducing the duration of convulsions (135.36 ± 0.76^{ns}) and $(98.38\pm0.57^*)$ when compared to the control and standard group. This revealed that medium and high doses of ethanolic leaf extract showed significant antiepileptic activity.

Groups	Treatment	Flexion	Extensor	Clonus	Stupor	HLE	% protection
		2.3±	$22.09 \pm$	35.16±	85.26±	$109.53 \pm$	
Ι	Control	0.36	0.86	1.05	0.51	1.43	0
		0.9±	9.36±	14.25±	30.58±	65.89±	
II	Phenytoin	0.11*	0.36**	1.32*	0.55*	0.65*	100
	Low	2.1±	15.25±	23.56±	41.25±	89.58±	
III	(100mg/kg)	0.10**	0.96*	0.53 ^{ns}	1.05*	1.45*	66.6
	Medium	2.9±	11.25±	29.56±	65.58±	65.89±	
IV	(200mg/kg)	0.40*	1.43*	1.05*	0.52*	1.05**	83.33
	High	1.9±	16.58±	20.58±	42.58±	78.85±	
IV	(400mg/kg)	0.49*	0.53*	0.51**	0.47*	0.51 ^{ns}	83.33

Maximal electric shock induced convulsions:						
Table 6 : Effect of ethanolic extract of P.pudica leaves						

Values are expressed as mean \pm SEM for 6 animals; ****p < 0.001, *p < 0.001 and *p < 0.05 Vs control.





In the MES model, the standard phenytoin showed a significant reduction in all seizure parameters compare to control group. It showed 100% of protection against seizure. All the doses of extract showed a significant reduction in seizure parameters as compared to the control group. The medium dose showed highest flexion $(2.9\pm0.40^*)$, clonus $(29.56\pm1.05^*)$ and stupor $(65.58\pm0.52^*)$ and high dose of extract showed highest extensor value (16.58 ± 0.53) as compared to the control group. HLE durations of low, medium and high doses are $89.58\pm3.56^*, 65.89\pm2.58^{**}$ and 78.85 ± 1.25^{ns} respectively. The medium and high doses of



ethanolic extract of leaves exhibited lowest period of HLE of $65.89 \pm 1.05^{**}$ and 78.85 ± 0.51^{ns} seconds indicating highest % percentage protection against




Stupor

seizure. whereas, the low dose of extract was less effective against MES seizure.



Extensor



Hindlimb extension



Figure6 : Animals showing different phases of convulsions

IV. CONCLUSION

The study reports the successful extraction, insilico study, acute oral toxicity study and evaluation of antiepileptic activity of the leaf extracts of plumeria pudica. In the present study, 10 phytoconstituents present in leaf were docked towards the MAPK13 complex with inhibitor (5EKO), which showed that beta-sitosterol (-5.462) had better docking score when compared to the standard diazepam (-4.738). The acute oral toxicity study of ethanolic leaf extract on mice was revealed that,the extract was found to be safe up to the tested dose of 2000mg/kg. Anti-epileptic activity was

evaluated using in-vivo methods by PTZ-induced convulsion and MES-induced convulsion. In PTZ model, the medium and high doses of ethanolic extract showed similar efficacy in increasing latency to convulsions (114.13 ± 1.36) and ($125.52\pm1.18^{*}$) and reducing the duration of convulsions (135.36 ± 0.76^{ns}) and ($98.38\pm0.57^{*}$) when compared to the standard group. In case of MES model, the medium and high doses of ethanolic extract of leaves exhibited lowest period of HLE of 65.89 ± 1.05 and 78.85 ± 0.51 seconds indicating highest % percentage protection against seizure. The phytochemicals present in the



ethanolic extract of leaf responsible for the antiepileptic acitivity.so, it can be concluded that leaf extacts of Plumeia pudica possess antiepileptic activity, it can be used as herbal medicine to treat seizure.

CONFLICT OF INTERESTS

The authors declare that there is no conflict of interest.

REFERENCES

- Tanko Y, Ejike Daniel E, Jimoh A, Yusuf M, A. M, Balarabe F, et al. Anticonvulsant Activity of Methanol Stem Bark Extract of Securinega Virosa (Euphobiaceae) in Mice. IOSR J Pharm Biol Sci. 2012;4:44– 7.https://doi.org/10.9790/3008-0414447.
- [2]. Rutuba C, Sharma P, Modi N. Preliminary Phytochemical Screening, Quantitative Estimation of Total Phenols, Total Flavonoids and Anti-oxidant Activity of Leaves of Plumeria pudica Jacq. Indian J.Sci.2021;12:32926–35.
- [3]. Suarez SN, Sanahuja G, Lopez P, Caldwell DL. First confirmed report of powdery mildew (Erysiphe sp.) on Plumeria pudica in the United States. New Dis Rep. 2017;36:3–3. <u>https://doi.org/10.5197/j.2044-</u> 0588.2017.036.003
- [4]. Bhardwaj P, Rathore GS. Investigation of Analgesic Activity of Roots and Flowers of Plumeria Pudica Linn. Turk Online J Qual Inq. 2021;12:6387–91.
- [5]. Prasad WWC, Viraj MPM, Philip R, Rani J, Bn S. Extraction of acetylcholine esterase inhibitors from plumeria pudica and analyzing its activity on zebrafish brain. World J Pharm Pharm Sci.2016;5(4):1781-91.
- [6]. Shabana K, Salahuddin, Mazumder A, Singh H, Kumar R, Tyagi S, Datt V, Shankar Sharma A, Shahar Yar M, Jawed Ahsan M, Kumar Yadav R. Synthesis, Characterization, In Silico and In Vivo Evaluation of Benzimidazole-Bearing Quinoline Schiff Bases as New Anticonvulsant Agents. ChemistrySelect. 2023 Jun 5;8(21):e202300209.
- [7]. OECD. Test No. 425: Acute Oral Toxicity: Up-and-Down Procedure. OECD; 2022. <u>https://doi.org/10.1787/9789264071049-</u> <u>en</u>.

- [8]. Chowdhury B, Acharya B, Sahu D. Anticonvulsant and antioxidant effect of hydroalcoholic extract of Valeriana wallichii rhizomes in acute and chronic models of epilepsy in albino rats. IJNPR Former Nat Prod Radiance NPR 2022;12(4):585–91. https://doi.org/10.56042/ijnpr.v12i4.45216
- [9]. Eggadi V, Kulandaivelu U, B S S, Rao Jupally V. Screening of the Anticonvulsant Activity of Some Isatin Derivatives in Experimental Seizure Models and Its Effect on Brain GABA Levels in Mice. Am J Pharmacol Sci. 2013;1(3):42–6. https://doi.org/10.12691/ajps-1-3-3.
- [10]. Singh NK, Laloo D, Garabadu D, Singh TD, Singh VP. Ichnocarpus frutescens Ameliorates Experimentally Induced Convulsion in Rats. Int Sch Res Not. 2014:1–9.

https://doi.org/10.1155/2014/434179.

- [11]. Manavi MA, Jafari RM, Shafaroodi H, Ejtemaei- Mehr S, Sharifzadeh M, Dehpour AR. Anticonvulsant effects of ivermectin on pentylenetetrazole- and maximal electroshock-induced seizures in mice: the role of GABAergic system and KATP channels. Heliyon. 2022;8(11): e11375.https://doi.org/10.1016/j.heliyon.2 022.e11375.
- Kumar DP, Kumar MS. Evaluation of Anticonvulsant Activity of Hydro Ethanolic Extract of Coccinia grandis in Mice. Sch Acad J Pharm. 2022;11(9):149– 54. https://doi.org/10.36347/sajp.2022.v11i09.

https://doi.org/10.36347/sajp.2022.v11i09. 005.